{"id":"W4379377976","doi":"10.1080/0284186x.2023.2216339","title":"FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study","year":2023,"lang":"en","type":"article","venue":"Acta Oncologica","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Eisai; Mylan; Ipsen; Astellas Pharma Canada; Takeda Pharmaceutical Company; Gilead Sciences; Roche; Novartis; GlaxoSmithKline Australia; Meso Scale Diagnostics; Sanofi; Merck; British Microcirculation Society; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Irinotecan; FOLFIRI; Population; Regimen; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Topotecan; Refractory (planetary science); Surgery; Lung cancer; Retrospective cohort study; Chemotherapy regimen; Oncology; Progressive disease; Cancer; Chemotherapy; Colorectal cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006149136,0.0002727426,0.0007263692,0.0002930013,0.000181593,0.00002274149,0.0002705313,0.000129565,0.000276022],"category_scores_gemma":[0.0008438951,0.0002111543,0.00008569782,0.001305838,0.0001078433,0.000104527,0.0003638077,0.0006598826,0.00005045654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002287072,"about_ca_system_score_gemma":0.0004999281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005710262,"about_ca_topic_score_gemma":0.002882696,"domain_scores_codex":[0.9974242,0.0001621305,0.0003941836,0.0006838189,0.000596737,0.0007389078],"domain_scores_gemma":[0.9986163,0.0004208568,0.0001504466,0.0004624419,0.0001798171,0.0001701116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001961177,0.001593928,0.9352182,0.0001923502,0.0002988004,0.001635394,0.005021658,0.0000250409,0.02945758,0.00001469486,0.02053132,0.004049902],"study_design_scores_gemma":[0.005992357,0.004266759,0.9774001,0.0001468627,0.0001052785,0.000002120566,0.00378336,0.00009218976,0.0003144004,0.00008106011,0.007576311,0.000239209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9759207,0.001190845,8.959484e-7,0.002018082,0.0002309804,0.002626821,0.0000318849,0.0003133157,0.0176665],"genre_scores_gemma":[0.9925768,0.001470941,0.0001491321,0.0002321506,0.0001700303,0.001234116,0.00001221329,0.00003804517,0.004116624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04218194,"threshold_uncertainty_score":0.8610623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03943207050000615,"score_gpt":0.385076322317816,"score_spread":0.3456442518178099,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}